3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
213
Lung Neoplasms
79
Triple Negative Breast Neoplasms
67
Breast Neoplasms
67
Ovarian Neoplasms
56
Squamous Cell Carcinoma of Head and Neck
49
Small Cell Lung Carcinoma
47
Fallopian Tube Neoplasms
37
Endometrial Neoplasms
34
Neoplasms
31
Parkinson Disease 4, Autosomal Dominant Lewy Body
28
Neoplasm Metastasis
28
Head and Neck Neoplasms
24
Prostatic Neoplasms
20
Carcinoma
19
Esophageal Neoplasms
18
Urinary Bladder Neoplasms
16
Colorectal Neoplasms
16
Uterine Cervical Neoplasms
15
Oropharyngeal Neoplasms
14
Carcinoma, Transitional Cell
14
Carcinoma, Squamous Cell
14
Esophageal Squamous Cell Carcinoma
13
Brain Neoplasms
12
Stomach Neoplasms
10
Pancreatic Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
10
Mouth Neoplasms
9
Laryngeal Neoplasms
9
Carcinoma, Ovarian Epithelial
9
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
Carboplatin
×
1 year
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled